Drug Trial Radar · NCT01966107
Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.
Last checked: Nov 19, 2026Latest source record: Dec 6, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,635
Actual
Start
Oct 16, 2013
Primary completion
Sep 21, 2017
Study completion Sep 21, 2017
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Oct 21, 2013
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Objectives of this study are to assess the safety of Aclidinium bromide on major adverse cardiovascular events (MACE), to assess the overall safety of Aclidinium bromide and to assess whether Aclidinium bromide reduces moderate or severe COPD exacerbations. This study is a double-blind, randomized, placebo controlled, parallel-group study to evaluate the effect of Aclidinium bromide on the cardiovascular safety and COPD exacerbations in patients with moderate to very severe COPD, as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria.
Conditions
- COPD
- Chronic Obstructive Pulmonary Disease
- Moderate to Very Severe COPD
Interventions
Aclidinium BromideDrug
400 μg, twice per day, oral administration via a multi-dose dry-powder inhaler (DPI)
PlaceboDrug
Dose matched placebo, twice per day, oral administration via a multi-dose dry-powder inhaler (DPI)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Per Subject Per Year During the First Year of TreatmentTime frame: 12 months
- Number of Participants With Major Adverse Cardiovascular Event (MACE) - on Study AnalysisTime frame: At Screening, Treatment period (upto 36 months) and Post-treatment follow-up (PTFU)
Locations
468 sites in 2 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Birmingham, Alabama
Research Site
Birmingham, Alabama
Research Site
Birmingham, Alabama
Research Site
Birmingham, Alabama
Research Site
Florence, Alabama
Research Site
Foley, Alabama
Research Site
Huntsville, Alabama
Research Site
Jasper, Alabama
Research Site
Mobile, Alabama
Research Site
Tuscaloosa, Alabama
Research Site
Chandler, Arizona
Research Site
Glendale, Arizona
Research Site
Mesa, Arizona
Research Site
Peoria, Arizona
Research Site
Phoenix, Arizona
Research Site
Phoenix, Arizona
Research Site
Phoenix, Arizona
Research Site
Phoenix, Arizona
Research Site
Tucson, Arizona
Research Site
Tucson, Arizona
Research Site
Tucson, Arizona
Research Site
Tucson, Arizona
Research Site
Tucson, Arizona
Research Site
Hot Springs, Arkansas
Research Site
Little Rock, Arkansas
Research Site
Little Rock, Arkansas
Research Site
Bakersfield, California
Research Site
Encinitas, California
Research Site
Escondido, California
Research Site
Fresno, California
Research Site
Gold River, California
Research Site
Huntington Beach, California
Research Site
La Mirada, California
Research Site
Laguna Hills, California
Research Site
Lincoln, California
Research Site
Loma Linda, California
Research Site
Los Angeles, California
Research Site
Los Angeles, California
Research Site
Los Angeles, California
Showing 40 of 468 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.